【摘要】 目的探讨腔镜辅助下乳腺癌保乳术结合表柔比星新辅助化疗治疗乳腺癌的临床疗效。方法选择96例Ⅰ~Ⅱ期乳腺癌患者为研究对象,其中行腔镜辅助下乳腺癌保乳术治疗者(腔镜组)50例,传统保乳术(传统组)治疗者46例,所有患者均给予表柔比星联合多西他赛(TE)新辅助化疗方案。比较2组5年生存率、复发率、手术效果及美容效果,记录化疗不良反应。结果腔镜组与传统组5年生存率分别为94.0%和95.7%,复发率为6.0%和6.5%(P>0.05);2组清扫淋巴结数无显著差异(P>0.05);腔镜组乳房美容优良率、平均引流量及拔管时间优于传统组(P<0.05);全组脱发、中性粒细胞下降及消化道反应不良反应发生率分别为89.6%、66.7%和41.7%,经对症处置后患者均完成治疗。结论腔镜辅助下乳腺癌保乳术结合表柔比星新辅助化疗临床疗效理想,对机体损伤小,药物不良反应可耐受。更多还原

【Abstract】 Objective To explore the effect of breast-conserving surgery assisted by mastoscopy combined with epirubicin neoadjuvant chemotherapy for breast cancer. Methods 96 cases of stage Ⅰ ~ Ⅱ breast cancer patients were selected as research subjects,including 50 cases of endoscopic group who underwent breast-conserving surgery assisted by mastoscopy and 46 cases of traditional group who received traditional breast-conserving surgery. All the patients were given epirubicin and docetaxel( TE scheme).5 year survival rate,recurrence rate,operation effect and cosmetic effects were compared between the 2 groups. The adverse reactions of chemotherapy were recorded. Results 5 year survival rates were 94. 0% and 95. 7%,recurrence rates were6. 0% and 6. 5% in endoscopic group and traditional group respectively( P > 0. 05); There were no significant difference in number of lymph node dissection between the 2 groups( P > 0. 05); Mean drainage and extubation time in endoscopic group was superior to traditional group( P < 0. 05); Alopecia,neutropenia and the reaction of digestive tract were 89. 6%,66. 7% and 41. 7%;All the patients completed the treatment after symptomatic treatment. Conclusion Breast-conserving surgery assisted by mastoscopy combined with epirubicin neoadjuvant chemotherapy for breast cancer has ideal curative effect with less injure for body and tolerable adverse reactions.更多还原